JP2004530642A - 障害のあるケラチノサイト活性に関係する疾患を診断および処置するための中コンダクタンス型カリウムチャネルおよびモジュレーターの使用 - Google Patents
障害のあるケラチノサイト活性に関係する疾患を診断および処置するための中コンダクタンス型カリウムチャネルおよびモジュレーターの使用 Download PDFInfo
- Publication number
- JP2004530642A JP2004530642A JP2002554120A JP2002554120A JP2004530642A JP 2004530642 A JP2004530642 A JP 2004530642A JP 2002554120 A JP2002554120 A JP 2002554120A JP 2002554120 A JP2002554120 A JP 2002554120A JP 2004530642 A JP2004530642 A JP 2004530642A
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- formula
- phenyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C1C(*)=C(*)NC(*)=C1* Chemical compound *C1C(*)=C(*)NC(*)=C1* 0.000 description 2
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10065475A DE10065475A1 (de) | 2000-12-28 | 2000-12-28 | Verwendung von "intermediate-conductance" Kaliumkanälen und Modulatoren zur Diagnose und Behandlung von Krankheiten mit gestörter Keratinozytenfunktion |
US27745301P | 2001-03-20 | 2001-03-20 | |
PCT/EP2001/015317 WO2002053171A2 (de) | 2000-12-28 | 2001-12-27 | Verwendung von 'intermediate-conductance kaliumkanälen und modulatoren zur diagnose und behandlung von krankheiten mit gestörter keratinozytenaktivität |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004530642A true JP2004530642A (ja) | 2004-10-07 |
JP2004530642A5 JP2004530642A5 (xx) | 2005-12-22 |
Family
ID=26008117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002554120A Pending JP2004530642A (ja) | 2000-12-28 | 2001-12-27 | 障害のあるケラチノサイト活性に関係する疾患を診断および処置するための中コンダクタンス型カリウムチャネルおよびモジュレーターの使用 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1345618B1 (xx) |
JP (1) | JP2004530642A (xx) |
AT (1) | ATE291435T1 (xx) |
CA (1) | CA2433041A1 (xx) |
WO (1) | WO2002053171A2 (xx) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10250870A1 (de) * | 2002-10-31 | 2004-05-13 | Switch Biotech Ag | Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung |
WO2004064835A1 (en) * | 2003-01-17 | 2004-08-05 | Neurosearch A/S | Use of ion channel modulating agents for treating pain |
US7851431B2 (en) * | 2005-07-27 | 2010-12-14 | Prescription Dispensing Laboratories | Treatment of actinic keratoses with calcium channel blockers |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4569935A (en) * | 1983-03-17 | 1986-02-11 | University Of Tennessee Research Corp. | Topical treatment of psoriasis with imidazole antibiotics |
EP0181793B1 (fr) * | 1984-10-16 | 1988-07-27 | Synthelabo | Dérivés de pipéridine, leur préparation et leur application en thérapeutique |
GB2273873A (en) * | 1992-12-23 | 1994-07-06 | Univ Sheffield | Treatment of psoriasis |
AU7733896A (en) * | 1995-11-13 | 1997-06-05 | Brandeis University | Regulation of cancer-causing tyrosine kinases by potassium ion conductance |
JP4052525B2 (ja) * | 1996-09-11 | 2008-02-27 | オレゴン ヘルス サイエンシーズ ユニバーシティー | 低及び中間コンダクタンスのカルシウム活性化されたカリウムチャネル及びその使用 |
AU1224599A (en) * | 1997-11-14 | 1999-06-07 | Neurosearch A/S | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction |
JPH11209302A (ja) * | 1998-01-21 | 1999-08-03 | Pola Chem Ind Inc | 抗掻痒剤 |
AU1648600A (en) * | 1998-12-04 | 2000-06-26 | Neurosearch A/S | Use of isatin derivatives as ion channel activating agents |
AU1549700A (en) * | 1998-12-04 | 2000-06-26 | Neurosearch A/S | Ion channel modulating agents |
CN1177831C (zh) * | 1998-12-04 | 2004-12-01 | 神经研究公司 | 作为离子通道调节剂的新的苯并咪唑啉酮一、苯并噁唑酮一或苯并噻唑啉酮衍生物 |
JP2002533318A (ja) * | 1998-12-22 | 2002-10-08 | ニューロサーチ、アクティーゼルスカブ | イオンチャネル調節剤 |
-
2001
- 2001-12-27 JP JP2002554120A patent/JP2004530642A/ja active Pending
- 2001-12-27 EP EP01272669A patent/EP1345618B1/de not_active Expired - Lifetime
- 2001-12-27 AT AT01272669T patent/ATE291435T1/de not_active IP Right Cessation
- 2001-12-27 WO PCT/EP2001/015317 patent/WO2002053171A2/de active IP Right Grant
- 2001-12-27 CA CA002433041A patent/CA2433041A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002053171A2 (de) | 2002-07-11 |
EP1345618A2 (de) | 2003-09-24 |
CA2433041A1 (en) | 2002-07-11 |
ATE291435T1 (de) | 2005-04-15 |
EP1345618B1 (de) | 2005-03-23 |
WO2002053171A3 (de) | 2003-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhao et al. | Targeting of discoidin domain receptor 2 (DDR2) prevents myofibroblast activation and neovessel formation during pulmonary fibrosis | |
Tanaka et al. | Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model | |
Mimeault et al. | Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies | |
Luo et al. | A novel profibrotic mechanism mediated by TGFβ‐stimulated collagen prolyl hydroxylase expression in fibrotic lung mesenchymal cells | |
US20040248099A1 (en) | Use of intermediate -conductance potassium channels and modulators for diagnosing and treating diseases having disturbed keratinocyte activity | |
US9072777B2 (en) | Method for screening substance having proangiogenic effect | |
Pandolfi et al. | Hedgehog-Gli signaling in basal cell carcinoma and other skin cancers: prospects for therapy | |
US12059403B2 (en) | Use of SWELL1 inhibitors and modulators to treat type 2 diabetes and obesity | |
US20090035275A1 (en) | Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of NAD | |
Szanda et al. | Participation of p38 MAPK and a novel-type protein kinase C in the control of mitochondrial Ca2+ uptake | |
Lin et al. | Oxidized LDL but not angiotensin II induces cardiomyocyte hypertrophic responses through the interaction between LOX-1 and AT1 receptors | |
JP2004530642A (ja) | 障害のあるケラチノサイト活性に関係する疾患を診断および処置するための中コンダクタンス型カリウムチャネルおよびモジュレーターの使用 | |
KR101077179B1 (ko) | Pig3를 이용한 dna 손상 보호방법 | |
Reichrath et al. | The vitamin D endocrine system of human sebocytes | |
Li et al. | ASIC1a induces mitochondrial apoptotic responses in acute lung injury | |
WO2001089581A1 (fr) | Compositions medicamenteuses renfermant le gene de la prostacyline synthase | |
JP2003000267A (ja) | Gタンパク質共役受容体ファミリーのポリペプチドまたはそれらをコードする核酸、および障害、例えば皮膚障害の診断または治療のためのそれらの使用、および薬理学的活性物質の同定のためのそれらの使用 | |
Zhang et al. | Phosphorylation dependent mitochondrial translocation of Nr4a3 provokes cardiomyocyte death | |
Suzuki et al. | The F2-Isoprostane: Thromboxane-prostanoid receptor signaling axis drives persistent fibroblast activation in pulmonary fibrosis | |
JPWO2009044787A1 (ja) | テノモジュリンを有効成分とする腱断裂性疾患治療剤 | |
JP2001322947A (ja) | 遺伝子ファミリーnm23のポリペプチドまたはこれらをコードする核酸の、皮膚または腸障害の診断または治療のための使用、およびそれらの、薬理学的に活性がある物質の同定のための使用 | |
Eichelbaum et al. | MAMMALIAN PEPTIDE TRANSPORTERS AS TARGETS FOR DRUG DELIVERY | |
Xue-ping et al. | Benazepril, an angiotensin converting enzyme inhibitor, inhibits the formation of advanced glycosylation end products and vascular lesions in spontaneous hypertension rats. | |
Böhm et al. | The human basophil–a novel target of the neuropeptide alpha‐melanocyte‐stimulating hormone | |
Hack et al. | Skin-Targeted Inhibition of PPAR β/δ by Selective Antagonists to Treat PPAR b/d-Mediated Psoriasis-Like Skin Disease In Vivo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041227 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080331 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080908 |